RemeGen Co., Ltd. (HKG:9995)
Hong Kong · Delayed Price · Currency is HKD 115.20
+4.80 (4.35%)
Apr 2, 2026, 4:08 PM HKT
RemeGen Employees
RemeGen had 3,048 employees as of December 31, 2025. The number of employees increased by 49 or 1.63% compared to the previous year.
Employees
3,048
Change (1Y)
49
Growth (1Y)
1.63%
Revenue / Employee
1.19M HKD
Profits / Employee
259.09K HKD
Market Cap
84.21B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3,048 | 49 | 1.63% |
| Dec 31, 2024 | 2,999 | -616 | -17.04% |
| Dec 31, 2023 | 3,615 | 283 | 8.49% |
| Dec 31, 2022 | 3,332 | 1,211 | 57.10% |
| Dec 31, 2021 | 2,121 | 755 | 55.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 21,435 |
| WuXi Biologics | 13,252 |
| Innovent Biologics | 7,502 |
| 3SBio | 6,268 |
| Shanghai Henlius Biotech | 3,762 |
| Akeso | 3,761 |
| Shanghai Junshi Biosciences | 2,903 |
| Sichuan Kelun-Biotech Biopharmaceutical | 2,045 |
RemeGen News
- 2 months ago - AbbVie, RemeGen partner on experimental solid tumor treatment - Reuters
- 6 months ago - 2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China - PRNewsWire
- 8 months ago - RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries - PRNewsWire
- 8 months ago - RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA - PRNewsWire
- 10 months ago - PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement - Business Wire
- 10 months ago - RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis - PRNewsWire
- 11 months ago - RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China - PRNewsWire
- 1 year ago - Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis - PRNewsWire